Cargando…

Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case–Control Study

PURPOSE: The aim of our study was to identify the diagnostic ability of free fatty acids (FFAs) in younger colorectal cancer (CRC) patients by comparing carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). METHODS: Patients screened for CRC at Fujian Medical University Union Hospit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Bin, Zhang, Junrong, Zheng, Qingzhu, Dong, Binhua, Wang, Meihua, Liu, Jin, Cao, Yingping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123087/
https://www.ncbi.nlm.nih.gov/pubmed/34007210
http://dx.doi.org/10.2147/CMAR.S307753
_version_ 1783692801219756032
author Zhu, Bin
Zhang, Junrong
Zheng, Qingzhu
Dong, Binhua
Wang, Meihua
Liu, Jin
Cao, Yingping
author_facet Zhu, Bin
Zhang, Junrong
Zheng, Qingzhu
Dong, Binhua
Wang, Meihua
Liu, Jin
Cao, Yingping
author_sort Zhu, Bin
collection PubMed
description PURPOSE: The aim of our study was to identify the diagnostic ability of free fatty acids (FFAs) in younger colorectal cancer (CRC) patients by comparing carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). METHODS: Patients screened for CRC at Fujian Medical University Union Hospital from January 2011 to December 2014 were recruited. Patients pathologically diagnosed with CRC or colorectal adenoma (CA) and healthy control participants were included. The enzyme endpoint method was applied to measure FFA levels. Receiver operating characteristic (ROC) curve analysis was performed to further evaluate the diagnostic ability of FFAs. RESULTS: FFA levels in late-stage patients (tumour-node-metastasis (TNM) stages III–IV) were higher than those in early-stage patients (TNM stages I–II) (P=0.02). The FFA levels in CRC patients were higher than those in controls of all ages, those younger than 50 years, males and females (P<0.001), and this difference was larger for patients younger than 50 years and females than for the all ages group. There was no significant difference in the FFA level between CA patients and healthy participants (P=0.53). The area under the curve (AUC) values of FFA, CEA, CA19-9, FFA+CEA, FFA+CA19-9 and FFA+CEA+CA19-9 distinguished CRC patients from controls at all ages, with values of 0.604, 0.731, 0.640, 0.754, 0.678 and 0.758, respectively; however, in the younger CRC patients (age≤50), the AUC values were 0.701, 0.735, 0.669, 0.798, 0.749, and 0.801. The AUC in female patients younger than 50 years was larger than that in males (0.769 vs 0.660), and this value was greater than the value for CEA in males (0.739) and females (0.729). CONCLUSION: The FFA level not only can complement the predictive ability of the CEA and CA19-9 levels but also has a superior predictive ability in female and younger patients with CRC. FFA levels may have a potential role in triage screening of early CRC.
format Online
Article
Text
id pubmed-8123087
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81230872021-05-17 Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case–Control Study Zhu, Bin Zhang, Junrong Zheng, Qingzhu Dong, Binhua Wang, Meihua Liu, Jin Cao, Yingping Cancer Manag Res Original Research PURPOSE: The aim of our study was to identify the diagnostic ability of free fatty acids (FFAs) in younger colorectal cancer (CRC) patients by comparing carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). METHODS: Patients screened for CRC at Fujian Medical University Union Hospital from January 2011 to December 2014 were recruited. Patients pathologically diagnosed with CRC or colorectal adenoma (CA) and healthy control participants were included. The enzyme endpoint method was applied to measure FFA levels. Receiver operating characteristic (ROC) curve analysis was performed to further evaluate the diagnostic ability of FFAs. RESULTS: FFA levels in late-stage patients (tumour-node-metastasis (TNM) stages III–IV) were higher than those in early-stage patients (TNM stages I–II) (P=0.02). The FFA levels in CRC patients were higher than those in controls of all ages, those younger than 50 years, males and females (P<0.001), and this difference was larger for patients younger than 50 years and females than for the all ages group. There was no significant difference in the FFA level between CA patients and healthy participants (P=0.53). The area under the curve (AUC) values of FFA, CEA, CA19-9, FFA+CEA, FFA+CA19-9 and FFA+CEA+CA19-9 distinguished CRC patients from controls at all ages, with values of 0.604, 0.731, 0.640, 0.754, 0.678 and 0.758, respectively; however, in the younger CRC patients (age≤50), the AUC values were 0.701, 0.735, 0.669, 0.798, 0.749, and 0.801. The AUC in female patients younger than 50 years was larger than that in males (0.769 vs 0.660), and this value was greater than the value for CEA in males (0.739) and females (0.729). CONCLUSION: The FFA level not only can complement the predictive ability of the CEA and CA19-9 levels but also has a superior predictive ability in female and younger patients with CRC. FFA levels may have a potential role in triage screening of early CRC. Dove 2021-05-10 /pmc/articles/PMC8123087/ /pubmed/34007210 http://dx.doi.org/10.2147/CMAR.S307753 Text en © 2021 Zhu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhu, Bin
Zhang, Junrong
Zheng, Qingzhu
Dong, Binhua
Wang, Meihua
Liu, Jin
Cao, Yingping
Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case–Control Study
title Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case–Control Study
title_full Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case–Control Study
title_fullStr Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case–Control Study
title_full_unstemmed Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case–Control Study
title_short Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case–Control Study
title_sort free fatty acid is a promising biomarker in triage screening for patients with colorectal cancer: a case–control study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123087/
https://www.ncbi.nlm.nih.gov/pubmed/34007210
http://dx.doi.org/10.2147/CMAR.S307753
work_keys_str_mv AT zhubin freefattyacidisapromisingbiomarkerintriagescreeningforpatientswithcolorectalcanceracasecontrolstudy
AT zhangjunrong freefattyacidisapromisingbiomarkerintriagescreeningforpatientswithcolorectalcanceracasecontrolstudy
AT zhengqingzhu freefattyacidisapromisingbiomarkerintriagescreeningforpatientswithcolorectalcanceracasecontrolstudy
AT dongbinhua freefattyacidisapromisingbiomarkerintriagescreeningforpatientswithcolorectalcanceracasecontrolstudy
AT wangmeihua freefattyacidisapromisingbiomarkerintriagescreeningforpatientswithcolorectalcanceracasecontrolstudy
AT liujin freefattyacidisapromisingbiomarkerintriagescreeningforpatientswithcolorectalcanceracasecontrolstudy
AT caoyingping freefattyacidisapromisingbiomarkerintriagescreeningforpatientswithcolorectalcanceracasecontrolstudy